ABL103 in Combination With Pembrolizumab, With or Without Taxane in Advanced or Metastatic Solid Tumors
Clinical trial NCT07158918 · RECRUITING
Trial details
- NCT number
- NCT07158918
- Sponsor
- ABL Bio, Inc.
- Status
- RECRUITING
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2025-08-06
- Primary completion
- 2027-12-02
- Enrollment
- 65
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.